[go: up one dir, main page]

WO2009118706A9 - The treatment of helminthic infections - Google Patents

The treatment of helminthic infections Download PDF

Info

Publication number
WO2009118706A9
WO2009118706A9 PCT/IB2009/051269 IB2009051269W WO2009118706A9 WO 2009118706 A9 WO2009118706 A9 WO 2009118706A9 IB 2009051269 W IB2009051269 W IB 2009051269W WO 2009118706 A9 WO2009118706 A9 WO 2009118706A9
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
helminthic infections
composition
human subjects
helminthic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/051269
Other languages
French (fr)
Other versions
WO2009118706A2 (en
WO2009118706A3 (en
Inventor
Charles George Scheepers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRI LAZ MEDS Pty Ltd
Original Assignee
TRI LAZ MEDS Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TRI LAZ MEDS Pty Ltd filed Critical TRI LAZ MEDS Pty Ltd
Publication of WO2009118706A2 publication Critical patent/WO2009118706A2/en
Publication of WO2009118706A3 publication Critical patent/WO2009118706A3/en
Publication of WO2009118706A9 publication Critical patent/WO2009118706A9/en
Anticipated expiration legal-status Critical
Priority to ZA2011/00468A priority Critical patent/ZA201100468B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a composition for use in the treatment of helminthic infections in human subjects, the composition including a combination of the following active ingredients in the following percentages by mass: 33% Praziquantel, 45% Mebendazole and 22% Niclosamide. The composition is particularly suitable for use in the treatment of human subjects with compromised immune systems.
PCT/IB2009/051269 2008-03-26 2009-03-26 The treatment of helminthic infections Ceased WO2009118706A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ZA2011/00468A ZA201100468B (en) 2008-03-26 2011-01-18 The treatment of helminthic infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200802695 2008-03-26
ZA2008/02695 2008-03-26

Publications (3)

Publication Number Publication Date
WO2009118706A2 WO2009118706A2 (en) 2009-10-01
WO2009118706A3 WO2009118706A3 (en) 2009-12-03
WO2009118706A9 true WO2009118706A9 (en) 2010-01-14

Family

ID=41114398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/051269 Ceased WO2009118706A2 (en) 2008-03-26 2009-03-26 The treatment of helminthic infections

Country Status (2)

Country Link
WO (1) WO2009118706A2 (en)
ZA (1) ZA201100468B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051633A1 (en) * 2010-10-15 2012-04-19 Tri Laz Meds Sa (Pty) Ltd The treatment of helminthic infections.
WO2013093790A1 (en) * 2011-12-22 2013-06-27 Shoket Latief A composition for reducing an hiv viral load comprising praziquantel, niclosamide and albendazole

Also Published As

Publication number Publication date
WO2009118706A2 (en) 2009-10-01
ZA201100468B (en) 2011-10-26
WO2009118706A3 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
WO2011061330A3 (en) Use of physiological cooling active ingredients, and agents containing such active ingredients
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
TW200833330A (en) Substituted dihydropyrazolones and their use
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
TN2011000370A1 (en) Alkylamine-substituted dicyanopyridine and amino acid ester prodrugs thereof
PT2222669E (en) Oxadiazole derivatives active on sphingosine-1-phosphate (sip)
CN102036649A8 (en) Arginine salts and their use in the treatment of oral diseases
WO2011049327A3 (en) A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof
WO2009130616A3 (en) Improved tlr3 agonist compositions
WO2013101932A3 (en) Triclosan-free antibacterial soap
WO2012154122A3 (en) A topical formulation for treatment of hyperkeratotic skin
WO2012135701A3 (en) Compositions and methods for the detection of anaplasma platys
MY150931A (en) Substituted oxazolidinones and their use
CA2818951A1 (en) Human lactoferrin derived peptide for use as an antigen masking agent
IL194353A0 (en) Lysobactin amides
WO2008092219A3 (en) Pharmaceutical composition comprising tramadol and ketoprofen
WO2009118706A9 (en) The treatment of helminthic infections
EP2801356A3 (en) DHA and EPA for the reduction of oxidative stress
WO2011139252A3 (en) Efervescent formulations comprising cefdinir
WO2010061220A3 (en) Novel processes and pure polymorphs
ZA200908583B (en) Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation
HK1201189A1 (en) Use of amphoteric surfactants for the prevention and treatment of pathogenic vaginal biofilms in vaginal infections
WO2010086617A3 (en) Phosphoantigens for the treatment of burkholderia infections
WO2009007257A3 (en) Advanced glycation end products as active ingredients

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09724528

Country of ref document: EP

Kind code of ref document: A2